Cogent Biosciences is a clinical-stage biotechnology company developing precision medicines for genetically defined diseases. Its lead candidate, bezuclastinib, is a selective KIT tyrosine kinase inhibitor aimed at mutations such as KIT D816V, with programs in systemic mastocytosis and gastrointestinal stromal tumors (GIST). The company focuses on targeted small-molecule therapies rather than commercialized product sales at this stage.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -73.5 | — |
| Q3 2025 | 0 | — | -80.9 | — |
| Q4 2025 | 0 | — | -102.5 | — |
| Q1 2026 | 0 | — | -97.3 | — |
| Q2 2026 | 0 | — | -96.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Remitly Global, Inc. (RELY), Sotera Health Company (SHC), Calumet, Inc. (CLMT), Nexstar Media Group, Inc. (NXST), Bank OZK (OZK), Red Rock Resorts, Inc. (RRR)